GlaxoSmithKline agreed to pay 14 million to resolve multistate litigation alleging that state government programs were compelled to pay inflated prices for the firm's anti-depressant drug Paxil because GSK engaged in patent fraud, antitrust violations and frivolous litigation to maintain a monopoly and block generic versions from entering the market.